Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples